You are here: Industry Insights > lanadelumab

News List

Takeda submits New Drug Application for lanadelumab in Japan pharmaceutical-business-review
March 18, 2021
Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
Hereditary angioedema treatment recommended by NICE europeanpharmaceuticalreview
September 20, 2019
Lanadelumab, a preventive treatment for hereditary angioedema, has been recommended as a cost-effective use of NHS resources.
Shire receives EU approval for Takhzyro pharmatimes
December 03, 2018
Takhzyro (lanadelumab) is a subcutaneous injection indicated for routine prevention of recurrent HAE attacks in patients aged 12 years and older.
Lanadelumab effective in reducing hereditary angioedema attacks europeanpharmaceuticalreview
November 30, 2018
Results of a clinical trial has led to the FDA approval of a monoclonal antibody drug called lanadelumab, to treat hereditary angioedema attacks…
Shire’s lanadelumab shown to significantly cut HAE attacks pharmatimes
November 19, 2018
Shire says it presented data showing that its experimental drug lanadelumab provides a significant and clinically meaningful reduction of hereditary angioedema (HAE) attacks.
Shire's investigational HAE treatment lanadelumab accepted for review by regulators in EU, Canada firstwordpharma
March 30, 2018
Shire announced Thursday that the European Medicines Agency has determined there is sufficient data to begin an accelerated assessment of its marketing application for the plasma kallikrein inhibitor lanadelumab.